Enoxaparin Sodium

Adults: Treatment of deep vein thrombosis, with or without pulmonary embolism, uses Enoxaparin Sodium subcutaneously at 100 anti-Xa IU/kg twice daily for 10 days, or 150 anti-Xa IU/kg once daily for 10 days. Oral anticoagulant therapy should be started when appropriate. Enoxaparin Sodium should be continued until a therapeutic anticoagulant effect has been achieved. For treatment of unstable angina and non-Q-wave myocardial infarction, given together with aspirin, the dose is 100 anti-Xa IU/kg subcutaneously twice daily for 2 to 8 days. It should be given at the same time as oral aspirin (100 to 325 mg once daily). In these patients Enoxaparin Sodium should be prescribed for a minimum of 2 days and continued until clinical stabilization. For prevention of thrombus formation in extra corporeal circulation during hemodialysis, the recommended dose is 100 anti-Xa IU/kg. If the patient has a high risk of hemorrhage, the dose should be reduced to 50 anti-Xa IU/kg for double vascular access or 75 anti-Xa IU/kg for single vascular access. During hemodialysis, Enoxaparin Sodium should be introduced into the arterial line of the circuit at the beginning of the dialysis session. For prophylaxis of venous thromboembolic disease in surgical patients, the dose depends on the type of surgery. Patients undergoing general surgery with a moderate risk of thromboembolism (e.g. abdominal surgery) receive 2000 anti-Xa IU (0.2 ml) or 4000 anti-Xa IU (0.4 ml) subcutaneously once daily for 7 to 10 days. The first injection should be given 2 hours before the surgical procedure. Patients undergoing orthopedic surgery with a high risk of thromboembolism receive 4000 anti-Xa IU (0.4 ml) subcutaneously once daily for 7 to 10 days, and here the first injection should be given 12 hours before the surgical procedure. A longer treatment duration may be appropriate in some patients. For example, continuing 4000 anti-Xa IU once daily for 3 weeks after the initial therapy has been proven to be beneficial in orthopaedic surgery. For prophylaxis of venous thromboembolic disease in medical patients, the dose is 4000 anti-Xa IU (0.4 ml) subcutaneously once daily for 6 to 14 days.